Blackbaud (BLKB) Losses Deepen, Undervalued Multiple Sharpens Focus on Path to Profitability

Blackbaud (BLKB) continues to operate at a loss, with net losses deepening at an annualized pace of 66.1% over the last five years. Revenue is forecast to grow by 3.9% per year, trailing the broader US market’s average of 10.3%. Despite these losses, market watchers are focused on Blackbaud’s projected shift to profitability within the next three years. Earnings are expected to climb at a rapid 50.95% annual rate over that period. The setup for investors is a combination of above-average earnings growth potential and a price-to-sales ratio (2.8x) that sits below both industry and peer averages, which could set the stage for sentiment to shift favorably if financial execution follows through.

See our full analysis for Blackbaud.

Now, let's put these headline numbers in context by comparing them against the most popular narratives in the market to see which themes stand up and where the story changes.

See what the community is saying about Blackbaud

NasdaqGS:BLKB Earnings & Revenue History as at Oct 2025
NasdaqGS:BLKB Earnings & Revenue History as at Oct 2025
Advertisement

Margins Poised for Dramatic Turnaround

  • Analysts see profit margins swinging from -24.5% today to 11.4% within the next three years, a major shift that could provide a crucial boost to earnings quality if achieved.
  • Consensus narrative frames the improved margin outlook as stemming from operational efficiencies and automation.
    • Ongoing investments in AI-driven initiatives are predicted to cut costs and lift gross and net margins, which could multiply Blackbaud's earnings power and set it apart from lagging rivals.
    • Margin expansion is also linked to higher renewal rates and sticky recurring revenues from cloud SaaS models, suggesting that expanded platform adoption may buffer the business even if revenue growth trails industry averages.
  • Consensus narrative spotlights the leap in profitability, but the path depends on ambitious execution. Will margin targets and product innovation prove sustainable in a slow-growth environment? 📊 Read the full Blackbaud Consensus Narrative.

Share Count Decline Offers a Hidden Tailwind

  • Analysts expect the number of shares outstanding to drop by 3.87% per year for the next three years, supporting per-share value gains beyond just core profit improvements.
  • Analysts' consensus view suggests that this share count reduction, combined with future earnings growth, could compress the company's PE ratio to 29.6x by 2028, below the current software industry average of 36.2x.
    • This may enhance performance for current shareholders even if top-line revenue growth remains modest compared to sector peers.
    • The step-down in share count helps offset dilution risk, which is often a key concern for software investors weighing longer-term upside.

Valuation Still Under the Industry Radar

  • Blackbaud's price-to-sales (P/S) ratio of 2.8x sits well below both peer (6.4x) and US software industry (5.2x) averages, establishing a clear value gap that could attract new buyers if growth targets are met.
  • According to the analysts' consensus narrative, this discount is backed by financial forecasts that, if realized, position Blackbaud for a re-rating closer to its sector:
    • A projected rise in revenue to $1.3 billion and earnings to $143.1 million by 2028 supports expectations for multiple expansion, should the company hit these benchmarks.
    • The current share price of $65.92 still trades at a discount to both the $76.00 analyst price target and to the DCF fair value of $85.93, underscoring embedded upside potential should consensus assumptions hold up against future results.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Blackbaud on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a different take on the figures? Share your perspective and shape a fresh narrative in just a few minutes by clicking Do it your way.

A great starting point for your Blackbaud research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

See What Else Is Out There

Blackbaud’s muted revenue growth and dependence on ambitious margin improvements make its profit outlook more sensitive to slowdowns or setbacks.

If you’d prefer companies delivering consistent, reliable progress, use our stable growth stocks screener (2108 results) to easily find stocks with steady year-over-year gains and reduced volatility risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Blackbaud might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:BLKB

Blackbaud

Engages in the providing AI-powered solutions in the United States and internationally.

Undervalued with acceptable track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
186 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0